Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can liver scarring predict heart trouble?

NCT ID NCT07791589

Knowledge-focused Sponsor: Özgür Bahadır Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

Researchers are examining whether liver fibrosis, measured by non-invasive scores, correlates with estimated 10-year cardiovascular risk in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). The study uses data from 271 adults aged 30 to 79 and focuses on how age affects this relationship. They will compare fibrosis scores like FIB-4 and FIB-3, along with metabolic markers, against the American Heart Association's PREVENT risk equations. The goal is to see if simple liver tests can help identify patients at higher risk for heart disease, heart failure, and related conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the link between liver fibrosis and heart risk is clear, doctors might use simple liver tests to flag patients who need closer heart monitoring.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The results may not apply to everyone with MASLD, and the risk estimates depend on the accuracy of the input data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

271 people

The number who actually took part.

Started

Jun 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with MASLD who were evaluated at the study center between January 1, 2024 and April 30, 2026 and met the eligibility criteria for the primary PREVENT cardiovascular risk analysis.

Ages

30 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 30 to 79 years. Metabolic dysfunction-associated steatotic liver disease (MASLD), defined by hepatic steatosis on ultrasonography together with at least one cardiometabolic risk factor. Clinical data available for calculation of the PREVENT cardiovascular risk estimates within the supported input ranges. Exclusion Criteria: * Alternative causes of chronic liver disease. One or more required PREVENT input variables outside the supported ranges: systolic blood pressure 90-200 mmHg, total cholesterol 130-320 mg/dL, HDL cholesterol 20-100 mg/dL, eGFR 15-140 mL/min/1.73 m², or BMI 18.5-39.9 kg/m². Prior cardiovascular disease, defined as a history of stroke, coronary artery disease, heart failure, atrial fibrillation, or peripheral arterial disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic dysfunction-associated steatotic liver disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic dysfunction-associated steatotic liver disease

Contacts and locations

Locations

  • Göztepe Prof. Dr. Süleyman Yalçın City Hospital

    Istanbul, 34722, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.